Lead sponsor
United Neuroscience Ltd.
2 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
2
Trials led
0
Ongoing
77
Total enrollment
4
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
2
Trials by status
Completed
1
Terminated
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) PatientsAlzheimer's diseasePh 2Completed43
An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311Study partner/caregiver requiredPh 2Terminated34